H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) shares dropped 49.5% during trading on Friday . The company traded as low as $2.02 and last traded at $2.02. Approximately 400 shares were traded during mid-day trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Price Performance
The business has a 50-day simple moving average of $2.02 and a 200 day simple moving average of $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than H-CYTE
- Stock Dividend Cuts Happen Are You Ready?
- FedEx Delivers Another Crushing Blow to Its Stock Price
- How Can Investors Benefit From After-Hours Trading
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- Energy and Oil Stocks Explained
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
